<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931097</url>
  </required_header>
  <id_info>
    <org_study_id>C15-46</org_study_id>
    <secondary_id>2016-A00792-49</secondary_id>
    <nct_id>NCT02931097</nct_id>
  </id_info>
  <brief_title>DBS of the MLR for Gait and Balance Disorders in PD Patients</brief_title>
  <acronym>GAITPARK</acronym>
  <official_title>Effects of Deep Brain Stimulation of the Mesencephalic Locomotor Region on Gait and Balance Disorders in Parkinson's Disease Patients : a Randomized, Double-blind, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gait and balance disorders represent the main motor disability in advanced Parkinson's
      disease. These symptoms are less or unresponsive to levodopa treatment and are considered to
      be a contraindication for deep brain stimulation of the subthalamic nucleus. Falls and
      freezing of gait are responsible for high morbidity (fractures, residential health care) and
      increased significantly mortality. The pathophysiology of gait and balance disorders is still
      poorly understood, but recent data obtained in animals and humans suggest that a degeneration
      of cholinergic neurons of the pedunculopontine nucleus (PPN), within the mesencephalic
      locomotor region, could play a crucial role. In line with this hypothesis, low-frequency
      stimulation of the pedunculopontine area, thought to increase the activity of the remaining
      cholinergic PPN neurons, has been proposed to alleviate gait and balance disorders in
      advanced PD patients. Here, the efficacy of deep brain stimulation of the mesencephalic
      locomotor region will be tested in 12 PD patients in a randomized, double-blind, cross-over,
      controlled study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the anticipatory postural adjustments between each deep brain stimulation condition</measure>
    <time_frame>3, 5, 7 months after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Pedunculopontine stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep brain stimulation of the pedunculopontine area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pontomesencephalic stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep brain stimulation of the pontomesencephalic area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No deep brain stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep brain stimulation</intervention_name>
    <description>Stimulating deep brain electrodes and pulse generator</description>
    <arm_group_label>Pedunculopontine stimulation</arm_group_label>
    <arm_group_label>Pontomesencephalic stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham stimulation</intervention_name>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age below 71 years

          -  severe form of Parkinson's Disease with disease duration &gt; 5 years

          -  presence of gait and/or balance disorders unresponsive to levodopa treatment,

          -  &gt; 40% decrease in others motor symptoms with levodopa treatment

          -  health insurance

          -  give signed informed written consent

        Exclusion Criteria:

          -  dementia (Mattis Dementia Rating Scale &lt; 129, MDRS),

          -  ongoing psychiatric disturbances,

          -  surgical contraindications

          -  significant brain lesions detected on MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Laure Welter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriellle Derocle</last_name>
    <email>gabrielle.derocle@inserm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique-Institut du Cerveau et de la Moelle Epiniere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Coudoin, Nurse</last_name>
      <phone>+33142165772</phone>
      <email>sylvie.coudoin@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Laure Welter, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine Karachi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Deep brain stimulation</keyword>
  <keyword>Mesencephalic locomotor region</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

